靶向 CD19 的 T 细胞结合抗体治疗自身免疫性疾病。
CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease.
机构信息
Cullinan Oncology, Inc. , Cambridge, MA, USA.
Institute for Immunology, Ludwig Maximilians University , Munich, Germany.
出版信息
J Exp Med. 2024 May 6;221(5). doi: 10.1084/jem.20240499. Epub 2024 Apr 8.
Abstract
Jennifer S. Michaelson, Chief Scientific Officer at Cullinan Oncology, and Patrick A. Baeuerle, scientific advisor to Cullinan Oncology and honorary professor in immunology at Ludwig Maximilians University Munich, discuss the use of CD19-specific T cell-engaging antibody therapies (TCEs) as therapeutics for autoimmune diseases.
摘要
詹妮弗·S·米凯莱森（Jennifer S. Michaelson），卡利南肿瘤学首席科学官，以及帕特里夏·A·拜厄勒（Patrick A. Baeuerle），卡利南肿瘤学科学顾问和慕尼黑路德维希-马克西米利安大学免疫学荣誉教授，讨论了 CD19 特异性 T 细胞结合抗体疗法（TCEs）作为自身免疫性疾病治疗药物的应用。
相似文献
1
CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease.靶向 CD19 的 T 细胞结合抗体治疗自身免疫性疾病。
J Exp Med. 2024 May 6;221(5). doi: 10.1084/jem.20240499. Epub 2024 Apr 8.
2
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.CLN-978，一种新型半衰期延长的 CD19/CD3/HSA 特异性 T 细胞结合抗体构建物，对低表达 CD19 的 B 细胞恶性肿瘤具有强大的活性。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007398.
3
CAR T-cell therapy in autoimmune diseases.嵌合抗原受体 T 细胞疗法在自身免疫性疾病中的应用。
Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22.
4
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.T 细胞结合抗体治疗实体瘤：挑战与机遇。
Curr Opin Oncol. 2022 Sep 1;34(5):552-558. doi: 10.1097/CCO.0000000000000869. Epub 2022 Jul 28.
5
CD19 CAR T-cell Clinical Outcome Is Associated with the Gut Microbiome.嵌合抗原受体 T 细胞（CAR T）治疗的临床结局与肠道微生物组相关。
Cancer Discov. 2022 May 2;12(5):1182. doi: 10.1158/2159-8290.CD-RW2022-052.
6
CAR T-Cell Therapy in Autoimmune Disease.自身免疫性疾病中的嵌合抗原受体T细胞疗法
N Engl J Med. 2024 May 2;390(17):1629. doi: 10.1056/NEJMc2403705.
7
CAR T-Cell Therapy in Autoimmune Disease.自身免疫性疾病中的嵌合抗原受体T细胞疗法
N Engl J Med. 2024 May 2;390(17):1628-1629. doi: 10.1056/NEJMc2403705.
8
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.使用靶向CD19的嵌合抗原受体T细胞治疗一名重症系统性硬化症（SSc）患者。
Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5.
9
CAR T cells: Building on the CD19 paradigm.嵌合抗原受体 T 细胞：以 CD19 为范例。
Eur J Immunol. 2021 Sep;51(9):2151-2163. doi: 10.1002/eji.202049064. Epub 2021 Aug 2.
10
Successful administration of CD19 chimeric antigen receptor T cells in association with severe cyanotic congenital heart disease.成功施用与严重青紫型先天性心脏病相关的CD19嵌合抗原受体T细胞。
Pediatr Blood Cancer. 2022 Jun;69(6):e29671. doi: 10.1002/pbc.29671. Epub 2022 Mar 16.
引用本文的文献
1
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications.成纤维细胞在免疫反应、炎症性疾病及治疗中的意义。
Nat Rev Rheumatol. 2025 May 14. doi: 10.1038/s41584-025-01259-0.
2
Mediation Mendelian randomization analysis of immune cell phenotypes and glioma risk: unveiling the regulation of cerebrospinal fluid metabolites.免疫细胞表型与胶质瘤风险的中介孟德尔随机化分析：揭示脑脊液代谢物的调控机制
Discov Oncol. 2025 May 9;16(1):712. doi: 10.1007/s12672-025-02499-y.
本文引用的文献
1
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法后的继发性癌症
N Engl J Med. 2024 Feb 15;390(7):584-586. doi: 10.1056/NEJMp2400209. Epub 2024 Jan 24.
2
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.CLN-978，一种新型半衰期延长的 CD19/CD3/HSA 特异性 T 细胞结合抗体构建物，对低表达 CD19 的 B 细胞恶性肿瘤具有强大的活性。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007398.
3
Manufacturing innovation to drive down cell therapy costs.推动细胞治疗成本降低的制造创新。
Trends Biotechnol. 2023 Oct;41(10):1216-1219. doi: 10.1016/j.tibtech.2023.04.006. Epub 2023 May 24.
Zotero 插件